- Home
- PUBM vs DCTH Comparison
PUBM vs DCTH Comparison
Compare PUBM & DCTH Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PUBM
- DCTH
- Stock Information
- Founded
- PUBM 2006
- DCTH 1988
- Country
- PUBM United States
- DCTH United States
- Employees
- PUBM N/A
- DCTH N/A
- Industry
- PUBM Computer Software: Prepackaged Software
- DCTH Medical/Dental Instruments
- Sector
- PUBM Technology
- DCTH Health Care
- Exchange
- PUBM Nasdaq
- DCTH Nasdaq
- Market Cap
- PUBM 406.5M
- DCTH 388.3M
- IPO Year
- PUBM 2020
- DCTH N/A
- Fundamental
- Price
- PUBM $8.46
- DCTH $9.63
- Analyst Decision
- PUBM Buy
- DCTH Strong Buy
- Analyst Count
- PUBM 11
- DCTH 4
- Target Price
- PUBM $18.05
- DCTH $24.25
- AVG Volume (30 Days)
- PUBM 652.2K
- DCTH 1.1M
- Earning Date
- PUBM 11-10-2025
- DCTH 11-04-2025
- Dividend Yield
- PUBM N/A
- DCTH N/A
- EPS Growth
- PUBM N/A
- DCTH N/A
- EPS
- PUBM N/A
- DCTH 0.06
- Revenue
- PUBM $292,208,000.00
- DCTH $70,240,000.00
- Revenue This Year
- PUBM N/A
- DCTH $146.50
- Revenue Next Year
- PUBM $1.40
- DCTH $37.19
- P/E Ratio
- PUBM N/A
- DCTH $173.73
- Revenue Growth
- PUBM 3.53
- DCTH 491.35
- 52 Week Low
- PUBM $7.01
- DCTH $8.87
- 52 Week High
- PUBM $17.74
- DCTH $18.23
- Technical
- Relative Strength Index (RSI)
- PUBM 49.21
- DCTH 35.52
- Support Level
- PUBM $8.37
- DCTH $9.70
- Resistance Level
- PUBM $8.94
- DCTH $12.70
- Average True Range (ATR)
- PUBM 0.27
- DCTH 0.72
- MACD
- PUBM 0.05
- DCTH -0.18
- Stochastic Oscillator
- PUBM 54.98
- DCTH 0.81
About PUBM PubMatic Inc.
PubMatic Inc is a supply-side platform provider in the digital advertising technology market. These platforms help publishers, which supply digital ad inventory, manage their inventory, selling a high percentage of their inventory (increase the ad fill rate) and maximizing revenue per ad sold (optimize yield). The company generates revenue mainly by taking a piece of the ad sales that it enables. Buyers on the platform include intermediary buyers, such as demand-side platforms, or advertisers and ad agencies directly. Geographically, the company generates the majority of its revenue from the United States, followed by EMEA and APAC.
About DCTH Delcath Systems Inc.
Delcath Systems Inc is an oncology company. It is focused on the treatment of primary and metastatic liver cancers. The firm's product, Melphalan Hydrochloride for Injection along with the Delcath Hepatic Delivery System, or Melphalan/HDS, is a drug and device combination product, designed to administer high-dose chemotherapy to the liver while controlling systemic exposure and associated side effects. The company operates in one reportable segment which includes the research, development, manufacture, and distribution of hepatic delivery systems for use in the treatment of specific conditions. The Company operates its business in the United States and Europe.